News

Bowmed Ibisqus Ltd is pleased to announce the launch of our Daptomycin vials distributed in strengths of 350mg & 500mg adding to our growing portfolio of injectable anti-infective medicines. Daptomycin is a cyclic lipopeptide antibiotic with potent bactericidal activity against a range of Gram-positive bacteria, including streptococci, coagulase-negative staphylococci, and Staphylococcus aureus, including methicillin-resistant S. […]

Bowmed Ibisqus Ltd is pleased to announce the launch of Benzylpenicillin sodium 1200mg powder for solution for injection/infusion, supplied as a pack of ten glass vials adding to our growing portfolio of injectable anti-infective medicines. A 600mg strength version of this product range will also be available in September 2026. Benzylpenicillin sodium, also known as […]

Following yesterday’s announcement that IBI – Istituto Biochimico Italiano Giovanni Lorenzini and its subsidiaries have joined the ACS Dobfar Group, Bowmed Ibisqus is pleased to begin an exciting new chapter as part of the wider ACS Dobfar organisation. For our customers, suppliers and partners, our focus remains unchanged – Bowmed will continue to support the […]

Bowmed Ibisqus is pleased to announce the launch of Furosemide 20mg/2ml (10mg/ml) ampoules, supplied as a pack of five amber glass ampoules. Furosemide is a loop diuretic commonly prescribed to reduce fluid accumulation and manage severe hypertension effectively. The amber glass ampoules are supplied with a recyclable cardboard tray and should be kept in the […]

Bowmed Ibisqus is pleased to announce the launch of Levobupivacaine IV, supplied as a pack of five clear glass ampoules. The product is available in three strengths: 25mg/10ml, 50mg/10ml, and 75mg/10ml, offering flexibility for a range of clinical applications. Levobupivacaine is a long‑acting local anaesthetic and analgesic widely used for surgical anaesthesia—including epidural, intrathecal, and […]

Bowmed Ibisqus is delighted to donate our annual Christmas fund to Caia Park Partnership, a community-led charity based in Wrexham dedicated to empowering individuals and strengthening local communities.

Bowmed Ibisqus is pleased to announce the launch of Paracetamol vials.  The product is a standard 1000mg/100ml (10mg/ml) dose presented in a 10 pack and adds to our Analgesics range.

Bowmed Ibisqus is pleased to announce the launch of Dopamine ampoules. The product is a 200mg/5ml dose presented in a 5 pack of ampoules and adds to our Cardiovascular range.

Bowmed Ibisqus is pleased to announce the launch of Sugammadex vials. The product is a 200mg/2ml dose presented in a 10-pack vial for intravenous administration as a single bolus injection.

Bowmed Ibisqus is pleased to announce the launch of a Ready to Use Ropivacaine Bag.  The product is a standard 400mg/200ml (2mg/ml) dose presented in a 5 pack and adds to our anaesthesia range.

Bowmed Ibisqus is pleased to announce the launch of Ertapenem 1g Vial in a 10 pack presentation.

The Team at Bowmed Ibisqus has decided this year to split our annual Christmas fund between two equally deserving initiatives.  Firstly, Crimebeat North Wales, a community youth charity and secondly Yellow and Blue (YAB) a local social enterprise non-profit organisation.

Bowmed Ibisqus is pleased to announce the launch of our Teicoplanin IV Vials distributed in strengths of 200mg and 400mg.

Bowmed Ibisqus is pleased to announce the launch of a Ready to Administer Levofloxacin Bag.  The product is a standard 500mg/100ml dose presented in a 10 pack and customers may prefer this more convenient dose form and the benefits it brings regarding reduction in glass waste.

2022 has brought great financial challenges to many families and this year the Team at Bowmed Ibisqus wanted to donate the annual Christmas fund to a local social enterprise non-profit organisation, Yellow and Blue (YAB), who are helping families affected by hardship this festive season.

Bowmed Ibisqus is pleased to announce the launch of a new dose format for Tranexamic Acid IV.

Our new 1g/10ml IV dose will offer healthcare professionals a more convenient administration method in the standard treatment of local or general fibrinolysis.

This year has brought us unprecedented challenges and we come to the end of the year reflecting on how it has impacted us all.  The charitable sector is one area that has had to work even harder this year to keep their support functions in place and for this reason Bowmed Ibisqus has decided to support two local charities with donations this Christmas in the hope that it will make a difference to the residents in our community.

Bowmed Ibisqus has expanded the range of Ready to Administer IV Bags with the recent launch of Clindamycin. This product has been developed in strengths of 300mg/50ml and 600mg/50ml with each pack containing 10 bags.

The Company is closely monitoring Government advice relating to the novel coronavirus COVID-19 and has implemented measures designed to reduce the risk of infection for our staff including, but not limited to, a stop on all non-essential business travel.

Voriconazole 200mg powder for solution for infusion vials have been launched this month in time for the new England Wave 12 contract.

The launch of Labetalol IV by Bowmed Ibisqus has brought necessary reinforcement of the UK supply chain for this critical hospital medicine following periods of shortage during 2019.

On the 19th October Chirk Castle was lit up along with the community of Chirk and surrounding areas during the Hope House Charity 5k Dark Run.  Bowmed Ibisqus were delighted to be asked to sponsor this local event that is set to raise over £7,000 of essential funds.

Bowmed Ibisqus is once again proud to announce that we have passed the Cyber Essentials assessment and been awarded the 2019 Cyber Essentials certificate by the National Cyber Security Centre.

Over the coming months our customers will observe the gradual replacement of our Rocuronium vials with an ampoule version. Bowmed Ibisqus expect the remaining stock of the vial presentations to be exhausted by the beginning of February 2020 and thereafter customers should move over to the ampoule product.

Bowmed Ibisqus was proud to support one of our valued colleagues when she took part in the London Landmarks half marathon on Sunday 24th March 2019!

Bowmed Ibisqus is delighted to announce the launch of Aciclovir IV on behalf of the MA Holder Laboratórios Azevedos.  This product will be distributed in a strength of 250mg per vial with each pack containing 5 vials.

During the 2018 Annual Joint Conference of the UKCPA Clinical Pharmacy Association and Pharmacy Management, Dr Ryan Hamilton received the Bowmed Ibisqus Antimicrobial Management Award.  The Award is intended to recognise innovation in antimicrobial management.

We are pleased to report that our Italian-based group company IBI Lorenzini has partnered with Tracelink to implement global serialisation solutions ahead of the February 2019 FMD deadline.

Bowmed Ibisqus is delighted to announce the launch of Ciprofloxacin IV on behalf of the MA Holder Villerton Invest.  This product will be distributed in strengths of 200mg/100ml and 400mg/200ml with each pack containing 5 bags.

Bowmed Ibisqus is delighted to announce the launch of Meropenem IV on behalf of the MA Holder Villerton Invest. This product will be distributed in strengths of 500mg and 1g with each pack containing 10 vials.

In some recent batches of this product there is a minor cosmetic difference from previous batches in the coloured rings around the top of the ampoules. Ampoules in previous batches have two white coloured rings around the top of the ampoule. In some of the new batches, customers might see ampoules with either one white […]

Bowmed Ibisqus is delighted to announce the launch of Flucloxacillin 2g IV on behalf of the MA Holder Ibigen Srl. This product complements the other strengths already available in this range of 250mg, 500mg and 1g. The product will be distributed in a single pack.

Bowmed Ibisqus is delighted to announce the launch of Vancomycin 500mg IV on behalf of the MA Holder Quimedical-Produtos Farmaceuticos.  This product will be distributed in a single pack containing a 500mg vial.

Bowmed Ibisqus is delighted to announce the launch of Tirofiban IV on behalf of the MA Holder Ibigen Srl.  This product will be distributed in a single pack containing a 12.5mg/250ml bag.

In the last two weeks we have received customer calls regarding the correct appearance for reconstituted Co-amoxiclav Powder for solution for injection or infusion.  If the product is reconstituted in accordance with the details in the Patient Information Leaflet (PIL), the colour of the resulting solution will be ‘a clear, colourless or pale straw coloured […]

Bowmed Ibisqus is delighted to announce the launch of Atosiban IV on behalf of the MA Holder Ibigen Srl. This product will be distributed in a 6.75mg/0.9ml ampoule and a 37.5mg/5ml vial. Please note that future batches of the 37.5mg/5ml vial will also include a warning on the front of the carton and label that […]

On the 6th September 2013 Bowmed Ibisqus launched the antiepileptic drug Levetiracetam 500mg/5ml Concentrate for solution for infusion in packs of 10 vials. The product has been listed with our nominated distributors and stock is available on a regional basis for any live contracts. If you would like to discuss Levetiracetam IV or any of […]

On the 1st July 2013 Bowmed Ibisqus launched Pantoprazole 40mg Powder for solution for injection/infusion.

On the 24th June 2013 Bowmed Ibisqus launched Rocuronium bromide in two strengths, 50mg/5ml and 100mg/10ml.

On the 23rd November 2012 Bowmed Ibisqus launched Amiodarone 150mg/3ml Concentrate for solution for injection or infusion.

On the 14th May 2012 Bowmed Ibisqus launched Esomeprazole 40mg powder for solution for infusion/injection. This new addition to our UK product range further expands our specialist range of generic proton pump inhibitors.

On the 1st March 2012 Bowmed Ibisqus launched Levofloxacin solution for infusion 500mg/100ml vials. This new addition to our UK product range further expands our specialism in the field of generic injectable antibacterial drugs.